ATE467688T1 - Antivirale antisense-verbindung und verfahren zur behandlung von arenavirus-infektion - Google Patents
Antivirale antisense-verbindung und verfahren zur behandlung von arenavirus-infektionInfo
- Publication number
- ATE467688T1 ATE467688T1 AT07752661T AT07752661T ATE467688T1 AT E467688 T1 ATE467688 T1 AT E467688T1 AT 07752661 T AT07752661 T AT 07752661T AT 07752661 T AT07752661 T AT 07752661T AT E467688 T1 ATE467688 T1 AT E467688T1
- Authority
- AT
- Austria
- Prior art keywords
- viral
- antisense compound
- infection
- arenavirus infection
- subunits
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 230000000692 anti-sense effect Effects 0.000 title abstract 3
- 230000000840 anti-viral effect Effects 0.000 title abstract 3
- 208000005989 Arenaviridae Infections Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 108020000999 Viral RNA Proteins 0.000 abstract 2
- 241000712892 Arenaviridae Species 0.000 abstract 1
- 108020004394 Complementary RNA Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 239000003184 complementary RNA Substances 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 230000017066 negative regulation of growth Effects 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
- C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78022806P | 2006-03-07 | 2006-03-07 | |
| PCT/US2007/005977 WO2007103529A2 (en) | 2006-03-07 | 2007-03-07 | Antisense antiviral compound and method for treating arenavirus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE467688T1 true ATE467688T1 (de) | 2010-05-15 |
Family
ID=38475578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07752661T ATE467688T1 (de) | 2006-03-07 | 2007-03-07 | Antivirale antisense-verbindung und verfahren zur behandlung von arenavirus-infektion |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7582615B2 (de) |
| EP (1) | EP2002018B1 (de) |
| AT (1) | ATE467688T1 (de) |
| AU (1) | AU2007223776B2 (de) |
| CA (1) | CA2644262C (de) |
| DE (1) | DE602007006457D1 (de) |
| WO (1) | WO2007103529A2 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004235396B2 (en) | 2003-04-29 | 2010-11-25 | Sarepta Therapeutics, Inc. | Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells |
| US20050288246A1 (en) | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
| US8129352B2 (en) | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| WO2007030691A2 (en) * | 2005-09-08 | 2007-03-15 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
| US8871746B2 (en) * | 2006-03-02 | 2014-10-28 | Kineta Four, LLC | Antiviral drugs for treatment of arenavirus infection |
| US8785407B2 (en) | 2006-05-10 | 2014-07-22 | Sarepta Therapeutics, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
| CA2691673A1 (en) * | 2007-06-29 | 2009-01-08 | Avi Biopharma, Inc. | Tissue specific peptide conjugates and methods |
| US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| AU2010319314C1 (en) | 2009-11-13 | 2016-09-01 | Sarepta Therapeutics, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| US9050373B2 (en) | 2010-05-13 | 2015-06-09 | The Charlotte-Mecklenburg Hospital Authority | Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same |
| KR101981705B1 (ko) | 2010-05-28 | 2019-05-24 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체 |
| US8198429B2 (en) | 2010-08-09 | 2012-06-12 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
| WO2012031243A2 (en) | 2010-09-03 | 2012-03-08 | Avi Biopharma, Inc. | dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS |
| BR112013020273A2 (pt) | 2011-02-08 | 2016-10-18 | Charlotte Mecklenburg Hospital | oligonucleotídeos antissenso |
| AU2011367230B2 (en) | 2011-05-05 | 2017-08-10 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| US9161948B2 (en) | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| KR20140097398A (ko) | 2011-11-18 | 2014-08-06 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 기능적으로-변형된 올리고뉴클레오티드 및 이의 서브유니트 |
| US11020417B2 (en) | 2015-06-04 | 2021-06-01 | Sarepta Therapeutics, Inc | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
| NZ755416A (en) | 2016-12-19 | 2023-05-26 | Sarepta Therapeutics Inc | Exon skipping oligomer conjugates for muscular dystrophy |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5217866A (en) * | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| US5506337A (en) * | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5185444A (en) * | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5034506A (en) * | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5166315A (en) * | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5521063A (en) * | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| JP2528107B2 (ja) * | 1985-03-15 | 1996-08-28 | サマ−トン，ジエ−ムス | ポリヌクレオチド測定試薬と方法 |
| JPH06501843A (ja) * | 1990-08-14 | 1994-03-03 | アイシス・ファーマシューティカルス・インコーポレーテッド | アンチセンスオリゴヌクレオチドによるインフルエンザａ型ウイルス，アン・アーバｈ２ｎ２株の阻害 |
| US7094765B1 (en) * | 1999-01-29 | 2006-08-22 | Avi Biopharma, Inc. | Antisense restenosis composition and method |
| KR20010102992A (ko) * | 1999-01-29 | 2001-11-17 | 추후보정 | 표적 ｒｎａ를 검출하는 비-침입적 방법 |
| EP1238071B1 (de) * | 1999-11-29 | 2008-04-23 | Avi Biopharma, Inc. | Gegen bakterielle 16s und 23s rrnas gerichtete ungeladene antisense oligonukleotide und deren verwendungen |
| WO2001049775A2 (en) * | 2000-01-04 | 2001-07-12 | Avi Biopharma, Inc. | Antisense antibacterial cell division composition and method |
| AU5752601A (en) * | 2000-05-04 | 2001-11-12 | Avi Biopharma Inc | Splice-region antisense composition and method |
| EP1301525B1 (de) * | 2000-07-06 | 2015-09-02 | Sarepta Therapeutics, Inc. | Transformation einer stammzellen enthaltenden, mit einem den wachstumsfaktor beta (tgf-beta) blockierenden mittel behandelten zusammensetzung und entsprechendes verfahren dazu |
| WO2003025139A2 (en) * | 2001-09-17 | 2003-03-27 | Mayo Foundation For Medical Education And Research | Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof |
| US6828105B2 (en) * | 2001-10-16 | 2004-12-07 | Avi Biopharma, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
-
2007
- 2007-03-07 CA CA2644262A patent/CA2644262C/en not_active Expired - Fee Related
- 2007-03-07 DE DE602007006457T patent/DE602007006457D1/de active Active
- 2007-03-07 AT AT07752661T patent/ATE467688T1/de not_active IP Right Cessation
- 2007-03-07 AU AU2007223776A patent/AU2007223776B2/en not_active Ceased
- 2007-03-07 WO PCT/US2007/005977 patent/WO2007103529A2/en not_active Ceased
- 2007-03-07 US US11/715,572 patent/US7582615B2/en active Active
- 2007-03-07 EP EP07752661A patent/EP2002018B1/de not_active Ceased
-
2009
- 2009-08-25 US US12/547,287 patent/US7855283B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7582615B2 (en) | 2009-09-01 |
| DE602007006457D1 (de) | 2010-06-24 |
| AU2007223776A1 (en) | 2007-09-13 |
| CA2644262C (en) | 2016-01-05 |
| WO2007103529A2 (en) | 2007-09-13 |
| WO2007103529A3 (en) | 2007-12-13 |
| US7855283B2 (en) | 2010-12-21 |
| AU2007223776B2 (en) | 2014-05-22 |
| EP2002018A2 (de) | 2008-12-17 |
| CA2644262A1 (en) | 2007-09-13 |
| EP2002018B1 (de) | 2010-05-12 |
| EP2002018A4 (de) | 2009-03-25 |
| US20100063133A1 (en) | 2010-03-11 |
| US20070274957A1 (en) | 2007-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602007006457D1 (de) | Antivirale antisense-verbindung und verfahren zur behandlung von arenavirus-infektion | |
| EP1937278A4 (de) | Antivirale antisense-verbindung und verfahren zur behandlung von picornavirus-infektion | |
| WO2007030691A3 (en) | Antisense antiviral compound and method for treating picornavirus infection | |
| WO2006047683A3 (en) | Antisense antiviral compound and method for treating influenza viral infection | |
| ATE540116T1 (de) | Antivirale antisense-verbindungen und verfahren zur behandlung von filovirus-infektionen | |
| ATE491791T1 (de) | Oligonukleotidanalog und verfahren zur behandlung von flavivirusinfektionen | |
| EP1507791A4 (de) | Antisense-antivirusmittel und verfahren zur behandlung einer ssrna-virusinfektion | |
| CY1124197T1 (el) | Antinohmatika πολυνουκλεοτιδια για να διεγειρεται παραλειψη εξονιου και μεθοδοι θεραπειας δυστροφιων | |
| WO2006033933A3 (en) | Antisense antiviral compound and method for treating ssrna viral infection | |
| CA2526893A1 (en) | Inhibition of the expression of huntingtin gene | |
| EP1623012A4 (de) | Antisense-antivirusmittel und verfahren zur behandlung einer ssrna-virusinfektion | |
| BR112012011381A2 (pt) | composto antiviral anti-senso e método para tratar infecção viral por influenza | |
| ATE550025T1 (de) | Behandlung neurodegenerativer erkrankungen mittels intrakranialer freisetzung von small- interfering-rna (sirna) | |
| ATE552347T1 (de) | Oligonukleotidverbindung und verfahren zur behandlung von nidovirusinfektionen | |
| NZ591416A (en) | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof | |
| RU2012114198A (ru) | Модуляция экспрессии гентингтина | |
| ATE460500T1 (de) | Zusammensetzungen und verfahren zur sirna- inhibition der angiogenese | |
| RU2018113276A (ru) | Антисмысловая нуклеиновая кислота | |
| DE602005026386D1 (de) | Antisense-oligonukleotide zur induktion von exon-skipping sowie verfahren zur verwendung davon | |
| WO2015023941A1 (en) | Oligonucleotides targeting euchromatin regions of genes | |
| ATE528008T1 (de) | Rnai-modulation von aha und ihre therapeutische verwendung | |
| ATE551343T1 (de) | Tetracyclische verbindungen zur behandlung von hepatitis c | |
| ATE505473T1 (de) | Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c | |
| WO2005013905A3 (en) | SENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ssRNA VIRAL INFECTION | |
| WO2007044468A3 (en) | Method to treat flavivirus infection with sirna |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |